COVID-19 drug efficient in reducing infection after 5 days - trial

Saturday, 06. March 2021 10:05

Merck and Ridgeback Biotherapeutics LP announced on Saturday the results of the phase 2a trial of their coronavirus drug molnupiravir, stating that it reduces the time to viral negativity. The study was carried out on 202 adults who had signs or symptoms of COVID-19 within 7 days and had a confirmed infection. Preliminary results showed a reduction in the infectious virus to 0% in five days.

"The secondary objective findings in this study, of a quicker decrease in infectious virus among individuals with early COVID-19 treated with molnupiravir, are promising and if supported by additional studies, could have important public health implications, particularly as the SARS-CoV-2 virus continues to spread and evolve globally," said Dr. William Fischer of the University of North Carolina School of Medicine.

Related Links: Merck KGaA
Author:
Breaking the News / DJ